Update: Novo Nordisk Loses India Case to Halt Dr. Reddy's Production of Generic Semaglutide

MT Newswires Live2025-12-05

(Updates with Novo Nordisk's response in the sixth paragraph.)

Novo Nordisk (NVO) has lost an Indian court case over whether Dr. Reddy's Laboratories can manufacture and export generic versions of its diabetes and weight-loss drugs, news outlets reported Thursday.

The Delhi High Court on Tuesday dismissed Novo Nordisk's petition to block Dr. Reddy's from producing Ozempic and Wegovy's active ingredient semaglutide, the reports said.

The ruling will allow Dr. Reddy's to produce semaglutide compounds and export them to countries where the patent has expired, the reports said.

The Indian patent for semaglutide is set to expire in March, while Novo Nordisk's patents in Brazil, China, and Canada are also set to expire next year, The Wall Street Journal reported.

Novo Nordisk can appeal the decision, the reports said.

Replying to an inquiry from MT Newswires, a Novo Nordisk spokesperson said, "We have received a copy of the judgment, and we are currently examining it."

Dr. Reddy's did not reply to MT Newswires' request for comment.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2589406896?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-05 18:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2589406896","market":"sg","top_or_hot":-1,"title":"Update: Novo Nordisk Loses India Case to Halt Dr. Reddy's Production of Generic Semaglutide","media":"MT Newswires Live","content":"<html><body><p> (Updates with <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>'s response in the sixth paragraph.)</p><p>Novo Nordisk (NVO) has lost an Indian court case over whether Dr. Reddy's Laboratories can manufacture and export generic versions of its diabetes and weight-loss drugs, news outlets reported Thursday.</p><p>The Delhi High Court on Tuesday dismissed Novo Nordisk's petition to block Dr. Reddy's from producing Ozempic and Wegovy's active ingredient semaglutide, the reports said.</p><p>The ruling will allow Dr. Reddy's to produce semaglutide compounds and export them to countries where the patent has expired, the reports said.</p><p>The Indian patent for semaglutide is set to expire in March, while Novo Nordisk's patents in Brazil, China, and Canada are also set to expire next year, The Wall Street Journal reported.</p><p>Novo Nordisk can appeal the decision, the reports said.</p><p>Replying to an inquiry from MT Newswires, a Novo Nordisk spokesperson said, \"We have received a copy of the judgment, and we are currently examining it.\"</p><p>Dr. Reddy's did not reply to MT Newswires' request for comment.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Update: Novo Nordisk Loses India Case to Halt Dr. Reddy's Production of Generic Semaglutide</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUpdate: Novo Nordisk Loses India Case to Halt Dr. Reddy's Production of Generic Semaglutide\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-05 18:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> (Updates with <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>'s response in the sixth paragraph.)</p><p>Novo Nordisk (NVO) has lost an Indian court case over whether Dr. Reddy's Laboratories can manufacture and export generic versions of its diabetes and weight-loss drugs, news outlets reported Thursday.</p><p>The Delhi High Court on Tuesday dismissed Novo Nordisk's petition to block Dr. Reddy's from producing Ozempic and Wegovy's active ingredient semaglutide, the reports said.</p><p>The ruling will allow Dr. Reddy's to produce semaglutide compounds and export them to countries where the patent has expired, the reports said.</p><p>The Indian patent for semaglutide is set to expire in March, while Novo Nordisk's patents in Brazil, China, and Canada are also set to expire next year, The Wall Street Journal reported.</p><p>Novo Nordisk can appeal the decision, the reports said.</p><p>Replying to an inquiry from MT Newswires, a Novo Nordisk spokesperson said, \"We have received a copy of the judgment, and we are currently examining it.\"</p><p>Dr. Reddy's did not reply to MT Newswires' request for comment.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RDY","symbol_name":"如瑞迪博士","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2589406896","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2589406896","pubTimestamp":1764931488,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Novo Nordisk  has lost an Indian court case over whether Dr. Reddy's Laboratories can manufacture and export generic versions of its diabetes and weight-loss drugs, news outlets reported Thursday.The Delhi High Court on Tuesday dismissed Novo Nordisk's petition to block Dr. Reddy's from producing Ozempic and Wegovy's active ingredient semaglutide, the reports said.The ruling will allow Dr. Reddy's to produce semaglutide compounds and export them to countries where the patent has expired, the reports said.The Indian patent for semaglutide is set to expire in March, while Novo Nordisk's patents in Brazil, China, and Canada are also set to expire next year, The Wall Street Journal reported.Novo Nordisk can appeal the decision, the reports said.Replying to an inquiry from MT Newswires, a Novo Nordisk spokesperson said, \"We have received a copy of the judgment, and we are currently examining it.\"Dr. Reddy's did not reply to MT Newswires' request for comment.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RDY":"如瑞迪博士","BK4596":"哈里斯概念","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","BK4007":"制药","BK7104":"黄金","NVO":"诺和诺德","LU0348744763.USD":"ALLIANZ ASIA PACIFIC INCOME \"A\" (USD) INC","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","BK4588":"碎股","BK4523":"印度概念","BK4585":"ETF&股票定投概念","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4557":"大麻股","BK4532":"文艺复兴科技持仓","BK4599":"减肥药"},"translate_title":"更新：诺和诺德在印度停止Dr.Reddy生产仿制药索马鲁肽的案件中败诉","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RDY":1.92,"NVO":1.95},"content_text":"(Updates with Novo Nordisk's response in the sixth paragraph.)Novo Nordisk (NVO) has lost an Indian court case over whether Dr. Reddy's Laboratories can manufacture and export generic versions of its diabetes and weight-loss drugs, news outlets reported Thursday.The Delhi High Court on Tuesday dismissed Novo Nordisk's petition to block Dr. Reddy's from producing Ozempic and Wegovy's active ingredient semaglutide, the reports said.The ruling will allow Dr. Reddy's to produce semaglutide compounds and export them to countries where the patent has expired, the reports said.The Indian patent for semaglutide is set to expire in March, while Novo Nordisk's patents in Brazil, China, and Canada are also set to expire next year, The Wall Street Journal reported.Novo Nordisk can appeal the decision, the reports said.Replying to an inquiry from MT Newswires, a Novo Nordisk spokesperson said, \"We have received a copy of the judgment, and we are currently examining it.\"Dr. Reddy's did not reply to MT Newswires' request for comment.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2589406896","isCrawlerRequest":true}